The launch of newer technology products with a wide range of
applications and the facility to deliver proteins, peptides, and
large molecules is expected to rake in market revenues, according
to a new report from market analysts Frost...
Despite a testing global economic climate, sales remained steady
and earnings before interest and taxes rose for German speciality
chemicals company Degussa in the first quarter of 2003. But guarded
optimism remains for 2003.
Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.
US manufacturer of vitamins, minerals, herbs and supplements
D&E Pharmaceuticals, has launched a contract manufacturing
services initiative, principally aimed at small to medium sized
US zuChem, a development-stage company that focuses on
commercialising manufacturing processes for glycochemicals, has
raised a considerable chunk of capital. Funds earmarked for
development of new sugar-based pharmaceutical intermediates.
In a bid to improve efficiency and reduce costs UK in vitro
diagnostics company Axis-Shield is to shift the manufacture of
certain products from its site in Oslo, Norway to the company's
global headquarters in Dundee, Scotland.
BioProgress, a UK company specialising in the manufacture of
non-gelatin capsules, looks set to become only the second UK
biopharmaceutical company to brave the equity markets this year
with a transfer of its listing Nasdaq's...
Operating profit for Danish enzyme company Novozymes improved
marginally in the first quarter of 2003, despite the impact of
unfavourable exchange rates. On the back of favourable developments
in net financials, the company reports...
UK life sciences group Amersham has reported first-quarter 2003
sales of £381 million (€544m), flat on the same period of 2002 but
up 6 per cent if unfavourable currency impacts and discontinued
product sales were excluded. The results...
US provider of virtual product development (VPD) technologies
MSC.Software has come up with a range of new software and services
packages targeted at the biomedical market and medical device
Danish Novo Nordisk plans to break ground on a €10 million
expansion of its insulin manufacturing facility in Clayton, US. The
company has awarded the contract to BE&K Engineering and Suitt
Construction for the 19,000-square-foot...
Outsourcing drug discovery functions is a rapidly growing trend
that has led to a nearly $2 billion (€1.7bn) industry worldwide,
according to a new study released this week by Kalorama
Information, and contract services in the field...